Explorative and targeted neuroproteomics in Alzheimer's disease

Blennow, 2006, Alzheimer's disease, Lancet, 368, 387, 10.1016/S0140-6736(06)69113-7

Masters, 1985, Amyloid plaque core protein in Alzheimer disease and Down syndrome, Proc. Natl. Acad. Sci. U. S. A., 82, 4245, 10.1073/pnas.82.12.4245

Goate, 1991, Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease, Nature, 349, 704, 10.1038/349704a0

Levy-Lahad, 1995, Candidate gene for the chromosome 1 familial Alzheimer's disease locus, Science, 269, 973, 10.1126/science.7638622

Sherrington, 1995, Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease, Nature, 375, 754, 10.1038/375754a0

Grundke-Iqbal, 1986, Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology, Proc. Natl. Acad. Sci. U. S. A., 83, 4913, 10.1073/pnas.83.13.4913

Nukina, 1986, One of the antigenic determinants of paired helical filaments is related to tau protein, J. Biochem., 99, 1541, 10.1093/oxfordjournals.jbchem.a135625

Rosen, 2013, Fluid biomarkers in Alzheimer's disease — current concepts, Mol. Neurodegener., 8, 20, 10.1186/1750-1326-8-20

Jack, 2010, Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade, Lancet Neurol., 9, 119, 10.1016/S1474-4422(09)70299-6

Hardy, 2006, Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal, J. Alzheimers Dis., 9, 151, 10.3233/JAD-2006-9S317

Karran, 2014, Antiamyloid therapy for Alzheimer's disease—are we on the right road?, N. Engl. J. Med., 370, 377, 10.1056/NEJMe1313943

Mann, 2013, The coming age of complete, accurate, and ubiquitous proteomes, Mol. Cell, 49, 583, 10.1016/j.molcel.2013.01.029

Zhang, 2005, Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases, J. Alzheimers Dis., 8, 377, 10.3233/JAD-2005-8407

Hokfelt, 2000, Neuropeptides—an overview, Neuropharmacology, 39, 1337, 10.1016/S0028-3908(00)00010-1

Johanson, 2008, Multiplicity of cerebrospinal fluid functions: new challenges in health and disease, Cerebrospinal Fluid Res., 5, 10, 10.1186/1743-8454-5-10

Korolainen, 2010, An update on clinical proteomics in Alzheimer's research, J. Neurochem., 112, 1386, 10.1111/j.1471-4159.2009.06558.x

Abdi, 2006, Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders, J. Alzheimers Dis., 9, 293, 10.3233/JAD-2006-9309

Chiasserini, 2014, Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset, J. Proteomics, 106, 191, 10.1016/j.jprot.2014.04.028

Ringman, 2012, Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations, Arch. Neurol., 69, 96, 10.1001/archneurol.2011.642

Zhang, 2005, Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid, Neurobiol. Aging, 26, 207, 10.1016/j.neurobiolaging.2004.03.012

Holtta, 2012, Peptidome analysis of cerebrospinal fluid by LC–MALDI MS, PLoS One, 7, e42555, 10.1371/journal.pone.0042555

Schulz-Knappe, 2001, Peptidomics: the comprehensive analysis of peptides in complex biological mixtures, Comb. Chem. High Throughput Screen., 4, 207, 10.2174/1386207013331246

Yuan, 2005, Human cerebrospinal fluid peptidomics, J. Mass Spectrom., 40, 176, 10.1002/jms.737

Zougman, 2008, Integrated analysis of the cerebrospinal fluid peptidome and proteome, J. Proteome Res., 7, 386, 10.1021/pr070501k

Jahn, 2011, Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers, PLoS One, 6, e26540, 10.1371/journal.pone.0026540

Wijte, 2012, A novel peptidomics approach to detect markers of Alzheimer's disease in cerebrospinal fluid, Methods, 56, 500, 10.1016/j.ymeth.2012.03.018

Dayon, 2008, Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags, Anal. Chem., 80, 2921, 10.1021/ac702422x

Percy, 2014, Multiplexed MRM with internal standards for cerebrospinal fluid candidate protein biomarker quantitation, J. Proteome Res., 10.1021/pr500317d

Hynd, 2003, Biochemical and molecular studies using human autopsy brain tissue, J. Neurochem., 85, 543, 10.1046/j.1471-4159.2003.01747.x

Braak, 1991, Neuropathological stageing of Alzheimer-related changes, Acta Neuropathol., 82, 239, 10.1007/BF00308809

Markesbery, 2006, Neuropathologic substrate of mild cognitive impairment, Arch. Neurol., 63, 38, 10.1001/archneur.63.1.38

Bigl, 1999, Activities of key glycolytic enzymes in the brains of patients with Alzheimer's disease, J. Neural Transm., 106, 499, 10.1007/s007020050174

Seipp, 1994, Isolation of glyceraldehyde 3-phosphate dehydrogenase (Gapdh) cDNA from the distal half of mouse chromosome 16: further indication of a link between Alzheimer's disease and glycolysis, Neurosci. Lett., 182, 91, 10.1016/0304-3940(94)90214-3

Fukuyama, 2001, The cerebrospinal fluid level of glial fibrillary acidic protein is increased in cerebrospinal fluid from Alzheimer's disease patients and correlates with severity of dementia, Eur. Neurol., 46, 35, 10.1159/000050753

Hjalmarsson, 2014, Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke, J. Cent. Nerv. Syst. Dis., 6, 51, 10.4137/JCNSD.S13821

Jesse, 2009, Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt–Jakob disease, J. Alzheimers Dis., 17, 541, 10.3233/JAD-2009-1075

Bjerke, 2011, Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease, J. Alzheimers Dis., 27, 665, 10.3233/JAD-2011-110566

Ohrfelt, 2011, Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease, Dement. Geriatr. Cogn. Disord. Extra, 1, 31, 10.1159/000323417

Steinacker, 2004, Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases, Neurosci. Lett., 370, 36, 10.1016/j.neulet.2004.07.061

Craft, 2013, Recent advances in quantitative neuroproteomics, Methods, 61, 186, 10.1016/j.ymeth.2013.04.008

Andreev, 2012, Label-free quantitative LC–MS proteomics of Alzheimer's disease and normally aged human brains, J. Proteome Res., 11, 3053, 10.1021/pr3001546

Donovan, 2012, Analysis of a membrane-enriched proteome from postmortem human brain tissue in Alzheimer's disease, Proteomics Clin. Appl., 6, 201, 10.1002/prca.201100068

Choi, 2004, Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases, J. Biol. Chem., 279, 13256, 10.1074/jbc.M314124200

Muller, 2008, Disease state, age, sex, and post-mortem time-dependent expression of proteins in AD vs. control frontal cortex brain samples, Curr. Alzheimer Res., 5, 562, 10.2174/156720508786898488

Gozal, 2009, Proteomics analysis reveals novel components in the detergent-insoluble subproteome in Alzheimer's disease, J. Proteome Res., 8, 5069, 10.1021/pr900474t

Piehowski, 2013, Sources of technical variability in quantitative LC–MS proteomics: human brain tissue sample analysis, J. Proteome Res., 12, 2128, 10.1021/pr301146m

Qian, 2006, Advances and challenges in liquid chromatography–mass spectrometry-based proteomics profiling for clinical applications, Mol. Cell. Proteomics, 5, 1727, 10.1074/mcp.M600162-MCP200

Manavalan, 2013, Brain site-specific proteome changes in aging-related dementia, Exp. Mol. Med., 45, e39, 10.1038/emm.2013.76

Begcevic, 2013, Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer's disease and age-matched control brains, Clin. Proteomics, 10, 5, 10.1186/1559-0275-10-5

Castano, 2013, Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterations, Neurochem. Int., 62, 145, 10.1016/j.neuint.2012.12.001

Chang, 2013, The synaptic proteome in Alzheimer's disease, Alzheimers Dement., 9, 499, 10.1016/j.jalz.2012.04.009

Di Domenico, 2011, Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects, J. Proteomics, 74, 1091, 10.1016/j.jprot.2011.03.033

Greber, 1999, Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down syndrome and Alzheimer's disease, Electrophoresis, 20, 928, 10.1002/(SICI)1522-2683(19990101)20:4/5<928::AID-ELPS928>3.0.CO;2-Z

Korolainen, 2005, Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain, Neurobiol. Dis., 20, 858, 10.1016/j.nbd.2005.05.021

Korolainen, 2006, Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain, Neurobiol. Aging, 27, 42, 10.1016/j.neurobiolaging.2004.11.010

Musunuri, 2014, Quantification of the brain proteome in Alzheimer's disease using multiplexed mass spectrometry, J. Proteome Res., 13, 2056, 10.1021/pr401202d

Perluigi, 2009, Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis, Proteomics Clin. Appl., 3, 682, 10.1002/prca.200800161

Schonberger, 2001, Proteomic analysis of the brain in Alzheimer's disease: molecular phenotype of a complex disease process, Proteomics, 1, 1519, 10.1002/1615-9861(200111)1:12<1519::AID-PROT1519>3.0.CO;2-L

Sultana, 2007, Proteomics analysis of the Alzheimer's disease hippocampal proteome, J. Alzheimers Dis., 11, 153, 10.3233/JAD-2007-11203

Sultana, 2006, Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD, Neurobiol. Aging, 27, 1564, 10.1016/j.neurobiolaging.2005.09.021

Sultana, 2006, Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach, Neurobiol. Dis., 22, 76, 10.1016/j.nbd.2005.10.004

Sultana, 2007, Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study, J. Cell. Mol. Med., 11, 839, 10.1111/j.1582-4934.2007.00065.x

Tsuji, 2002, Proteomic profiling and neurodegeneration in Alzheimer's disease, Neurochem. Res., 27, 1245, 10.1023/A:1020941929414

Zahid, 2014, Differential expression of proteins in brain regions of Alzheimer's disease patients, Neurochem. Res., 39, 208, 10.1007/s11064-013-1210-1

Anderson, 2002, The human plasma proteome: history, character, and diagnostic prospects, Mol. Cell. Proteomics, 1, 845, 10.1074/mcp.R200007-MCP200

Andreasson, 2007, Aspects of beta-amyloid as a biomarker for Alzheimer's disease, Biomark. Med, 1, 59, 10.2217/17520363.1.1.59

Vassar, 2011, The beta-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease, Alzheimers Res. Ther., 3, 20, 10.1186/alzrt82

Steiner, 2008, Intramembrane proteolysis by gamma-secretase, J. Biol. Chem., 283, 29627, 10.1074/jbc.R800010200

Portelius, 2011, A novel pathway for amyloid precursor protein processing, Neurobiol. Aging, 32, 1090, 10.1016/j.neurobiolaging.2009.06.002

Glenner, 1984, Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein, Biochem. Biophys. Res. Commun., 120, 885, 10.1016/S0006-291X(84)80190-4

Seubert, 1992, Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids, Nature, 359, 325, 10.1038/359325a0

Motter, 1995, Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease, Ann. Neurol., 38, 643, 10.1002/ana.410380413

Tabaton, 1994, Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid, Biochem. Biophys. Res. Commun., 200, 1598, 10.1006/bbrc.1994.1634

Van Nostrand, 1992, Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients, Proc. Natl. Acad. Sci. U. S. A., 89, 2551, 10.1073/pnas.89.7.2551

Albert, 2011, The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement., 7, 270, 10.1016/j.jalz.2011.03.008

Nalivaeva, 2012, Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease?, J. Neurochem., 120, 167, 10.1111/j.1471-4159.2011.07510.x

Portelius, 2011, Novel abeta isoforms in Alzheimer's disease — their role in diagnosis and treatment, Curr. Pharm. Des., 17, 2594, 10.2174/138161211797416039

Vigo-Pelfrey, 1993, Characterization of beta-amyloid peptide from human cerebrospinal fluid, J. Neurochem., 61, 1965, 10.1111/j.1471-4159.1993.tb09841.x

Brinkmalm, 2012, An online nano-LC–ESI–FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid beta and amyloid precursor protein in human and cat cerebrospinal fluid, J. Mass Spectrom., 47, 591, 10.1002/jms.2987

Coric, 2012, Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease, Arch. Neurol., 69, 1430, 10.1001/archneurol.2012.2194

Portelius, 2010, A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease, Alzheimers Res. Ther., 2, 7, 10.1186/alzrt30

Korecka, 2014, Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta(4)(2) in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry, J. Alzheimers Dis., 41, 441, 10.3233/JAD-132489

Lame, 2011, Quantitation of amyloid beta peptides Abeta(1–38), Abeta(1–40), and Abeta(1–42) in human cerebrospinal fluid by ultra-performance liquid chromatography–tandem mass spectrometry, Anal. Biochem., 419, 133, 10.1016/j.ab.2011.08.010

Pannee, 2013, A selected reaction monitoring (SRM)-based method for absolute quantification of Abeta38, Abeta40, and Abeta42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls, J. Alzheimers Dis., 33, 1021, 10.3233/JAD-2012-121471

Leinenbach, 2014, Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid, Clin. Chem., 60, 987, 10.1373/clinchem.2013.220392

Brinkmalm, 2013, Soluble amyloid precursor protein alpha and beta in CSF in Alzheimer's disease, Brain Res., 1513, 117, 10.1016/j.brainres.2013.03.019

Schedin-Weiss, 2014, The role of protein glycosylation in Alzheimer disease, FEBS J., 281, 46, 10.1111/febs.12590

Halim, 2011, Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid, Proc. Natl. Acad. Sci. U. S. A., 108, 11848, 10.1073/pnas.1102664108

Perdivara, 2009, Elucidation of O-glycosylation structures of the beta-amyloid precursor protein by liquid chromatography–mass spectrometry using electron transfer dissociation and collision induced dissociation, J. Proteome Res., 8, 631, 10.1021/pr800758g

Portelius, 2010, Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid, Exp. Neurol., 223, 351, 10.1016/j.expneurol.2009.06.011

Chen, 2013, Quantification of amyloid precursor protein isoforms using quantification concatamer internal standard, Anal. Chem., 85, 303, 10.1021/ac3033239

Utermann, 1977, Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man, Nature, 269, 604, 10.1038/269604a0

Rall, 1982, Human apolipoprotein E. The complete amino acid sequence, J. Biol. Chem., 257, 4171, 10.1016/S0021-9258(18)34702-1

Weisgraber, 1981, Human E apoprotein heterogeneity. Cysteine–arginine interchanges in the amino acid sequence of the apo-E isoforms, J. Biol. Chem., 256, 9077, 10.1016/S0021-9258(19)52510-8

Liu, 2013, Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy, Nat. Rev. Neurol., 9, 106, 10.1038/nrneurol.2012.263

Cruchaga, 2012, Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease, Hum. Mol. Genet., 21, 4558, 10.1093/hmg/dds296

Martinez-Morillo, 2014, Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls, Acta Neuropathol., 127, 633, 10.1007/s00401-014-1266-2

Vanmechelen, 2000, Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization, Neurosci. Lett., 285, 49, 10.1016/S0304-3940(00)01036-3

Portelius, 2008, Characterization of tau in cerebrospinal fluid using mass spectrometry, J. Proteome Res., 7, 2114, 10.1021/pr7008669

McAvoy, 2014, Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry, Clin. Chem., 60, 683, 10.1373/clinchem.2013.216515

Brinkmalm, 2014, Targeting synaptic pathology with a novel affinity mass spectrometry approach, Mol. Cell. Proteomics, 13, 2584, 10.1074/mcp.M114.040113

Brinkmalm, 2014, SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease, Mol. Neurodegener., 9, 53, 10.1186/1750-1326-9-53

Kvartsberg, 2014

Chang, 2014, Quantitative multiple reaction monitoring analysis of synaptic proteins from human brain, J. Neurosci. Methods, 227, 189, 10.1016/j.jneumeth.2014.02.016

Chang, 2014, Targeted quantitative analysis of synaptic proteins in Alzheimer's disease brain, Neurochem. Int., 75, 66, 10.1016/j.neuint.2014.05.011

Skorobogatko, 2011, Human Alzheimer's disease synaptic O-GlcNAc site mapping and iTRAQ expression proteomics with ion trap mass spectrometry, Amino Acids, 40, 765, 10.1007/s00726-010-0645-9

Guerreiro, 2013, TREM2 variants in Alzheimer's disease, N. Engl. J. Med., 368, 117, 10.1056/NEJMoa1211851

Jonsson, 2013, Variant of TREM2 associated with the risk of Alzheimer's disease, N. Engl. J. Med., 368, 107, 10.1056/NEJMoa1211103

Mattsson, 2011, Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility, Neruomol. Med., 13, 151, 10.1007/s12017-011-8147-9

Olsson, 2013, Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia, J. Alzheimers Dis., 33, 45, 10.3233/JAD-2012-120787

Varghese, 2013, Chitotriosidase — a putative biomarker for sporadic amyotrophic lateral sclerosis, Clin. Proteomics, 10, 19, 10.1186/1559-0275-10-19

Chen, 2013, Mass spectrometry assessment of ubiquitin carboxyl-terminal hydrolase L1 partitioning between soluble and particulate brain homogenate fractions, Anal. Chem., 85, 6011, 10.1021/ac400831z

Mondello, 2014, CSF alpha-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders, Parkinsonism Relat. Disord., 20, 382, 10.1016/j.parkreldis.2014.01.011

Chen, 2012, Mass spectrometry quantification of clusterin in the human brain, Mol. Neurodegener., 7, 41, 10.1186/1750-1326-7-41

Zhang, 2012, Targeted proteomics for quantification of histone acetylation in Alzheimer's disease, Proteomics, 12, 1261, 10.1002/pmic.201200010

Choi, 2013, Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer's disease biomarker candidates, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 930, 129, 10.1016/j.jchromb.2013.05.003

Fonteh, 2007, Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects, Amino Acids, 32, 213, 10.1007/s00726-006-0409-8

Krastins, 2013, Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum, Clin. Biochem., 46, 399, 10.1016/j.clinbiochem.2012.12.019

IJsselstijn, 2011, Serum clusterin levels are not increased in presymptomatic Alzheimer's disease, J. Proteome Res., 10, 2006, 10.1021/pr101221h

Eriksson, 2007, Improving the success rate of proteome analysis by modeling protein-abundance distributions and experimental designs, Nat. Biotechnol., 25, 651, 10.1038/nbt1315

McAlister, 2012, Increasing the multiplexing capacity of TMTs using reporter ion isotopologues with isobaric masses, Anal. Chem., 84, 7469, 10.1021/ac301572t

Lescuyer, 2007, How shall we use the proteomics toolbox for biomarker discovery?, J. Proteome Res., 6, 3371, 10.1021/pr0702060

Hernandez, 2014, Why have so few proteomic biomarkers “survived” validation? (Sample size and independent validation considerations), Proteomics, 14, 1587, 10.1002/pmic.201300377

Nuzzo, 2014, Scientific method: statistical errors, Nature, 506, 150, 10.1038/506150a

Anderson, 2005, The roles of multiple proteomic platforms in a pipeline for new diagnostics, Mol. Cell. Proteomics, 4, 1441, 10.1074/mcp.I500001-MCP200

Rifai, 2006, Protein biomarker discovery and validation: the long and uncertain path to clinical utility, Nat. Biotechnol., 24, 971, 10.1038/nbt1235

Bossuyt, 2003, Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for reporting of diagnostic accuracy, Clin. Chem., 49, 1, 10.1373/49.1.1

Noel-Storr, 2014, Reporting standards for studies of diagnostic test accuracy in dementia: the STARDdem initiative, Neurology, 83, 364, 10.1212/WNL.0000000000000621

Castano, 2006, Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects, Neurol. Res., 28, 155, 10.1179/016164106X98035

Davidsson, 2002, Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients, Neuroreport, 13, 611, 10.1097/00001756-200204160-00015

Puchades, 2003, Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease, Brain Res. Mol. Brain Res., 118, 140, 10.1016/j.molbrainres.2003.08.005

Korolainen, 2007, Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease, Clin. Chem., 53, 657, 10.1373/clinchem.2006.078014

Cheon, 2001, Decreased protein levels of stathmin in adult brains with Down syndrome and Alzheimer's disease, J. Neural Transm. Suppl., 281

Shiozaki, 2004, Proteome analysis of brain proteins in Alzheimer's disease: subproteomics following sequentially extracted protein preparation, J. Alzheimers Dis., 6, 257, 10.3233/JAD-2004-6306

Sultana, 2006, Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: a redox proteomics analysis, Neurobiol. Aging, 27, 918, 10.1016/j.neurobiolaging.2005.05.005

Pamplona, 2005, Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets, J. Biol. Chem., 280, 21522, 10.1074/jbc.M502255200

Papassotiropoulos, 2006, Genetics, transcriptomics, and proteomics of Alzheimer's disease, J. Clin. Psychiatry, 67, 652, 10.4088/JCP.v67n0418

Emilsson, 2006, Alzheimer's disease: mRNA expression profiles of multiple patients show alterations of genes involved with calcium signaling, Neurobiol. Dis., 21, 618, 10.1016/j.nbd.2005.09.004

Twine, 2011, Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer's disease, PLoS One, 6, e16266, 10.1371/journal.pone.0016266

Zhang, 2005, Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease, J. Alzheimers Dis., 7, 125, 10.3233/JAD-2005-7205

Baig, 2010, Distribution and expression of picalm in Alzheimer disease, J. Neuropathol. Exp. Neurol., 69, 1071, 10.1097/NEN.0b013e3181f52e01

Vogelgesang, 2004, The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease, Curr. Alzheimer Res., 1, 121, 10.2174/1567205043332225

Vogelgesang, 2002, Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans, Pharmacogenetics, 12, 535, 10.1097/00008571-200210000-00005